Ginkgo Bioworks focuses on its Foundry and Code Base assets to offer R&D services and drive down costs for clients. The company secures a significant deal with Pfizer in the drug discovery category, ...

Ginkgo Bioworks continues to face a weak demand environment, which has contributed to a lack of growth in recent years. Learn ...

Ginkgo Bioworks is cutting costs and laying off staff after losing $166 million in the first quarter. Revenue from its disease-monitoring business surged during the COVID-19 pandemic but was down more ...

Ginkgo Bioworks said it would lay off more than one-third of its workers as the Boston life sciences firm slashes costs in the face of plunging revenues. The company, which specializes in cell ...

Ginkgo Bioworks (NYSE: DNA) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Ginkgo Bioworks' CEO explains ...

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC GLBRC's mission involves numerous ...

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo ...